Hansen Medical Inc. announced the shipment of the Magellan Robotic System to Holy Name Medical Center in Teaneck, New Jersey, the first hospital in the New York/New Jersey metropolitan area to purchase a system.

Critical advancements in modern technology will play an integral role in progressing the Future of Healthcare, according to a new survey sponsored by Polycom, Inc. (Nasdaq: PLCM).  The study, which polled more than 1,000 healthcare industry professionals from around the world, anticipated that over the next decade, a growing and aging population globally will lead to challenges in quality healthcare, including funding, easy access and a strain on current healthcare infrastructure.

SentreHeart Inc. announced that it has received CE Mark approval for the Lariat Surgical Left Atrial Appendage (LAA) Suture Delivery Device. The Lariat Surgical LAA device is a suture-based solution for soft tissue closure, including the LAA. European surgeons can now offer their patients precise, user-controlled delivery of a 50mm pre-tied suture loop through traditional open surgical procedures or through an access port as small as 5mm.

St. Jude Medical Inc. announced the company has received CE Mark approval for the HeartMate 3 Left Ventricular Assist System (LVAS). HeartMate 3 is a cardiac support option for advanced heart failure patients who are awaiting transplantation, are not candidates for heart transplantation or are in myocardial recovery.

Stereotaxis Inc. announced the worldwide launch of Respiratory Compensation, a new software feature of the company’s Niobe remote magnetic navigation system.

A large observational registry found that initial aortic valve replacement (AVR) in asymptomatic patients with severe aortic stenosis (AS) was associated with a lower risk of mortality and heart failure hospitalization compared with a conservative treatment strategy.

Results from the multicenter, prospective, randomized PANDA III trial indicate that the BuMA sirolimus-eluting stent (SES) was non-inferior to the Excel SES for the primary endpoint of target lesion failure at one year. The trial specifically examined whether the rate of drug elution and polymer absorption affects the clinical outcomes of two bioresorbable polymer-based drug-eluting stents (DES).

OrbusNeich announced the presentation of the one-year clinical outcomes from the 1,000-patient REMEDEE Registry at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting, Oct. 11-15 in San Francisco. Data was presented by Robbert de Winter, M.D., Ph.D., of the Academic Medical Center, Amsterdam and principal investigator of the study.

Medinol announced in September the completion of enrollment in its BIONICS trial to evaluate the safety and effectiveness of a new coronary stent system, the first-ever elastomeric drug eluting stent (eDES).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now